| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1dd98ad4ee076841fec541542f952f58 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-31
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-482
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-164 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-31 |
| filingDate |
2002-05-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2004-12-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4d8b9471d7fd90ae9b7e1e09086ef34d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ef379c06db1b89599197e9bd454cfd69 |
| publicationDate |
2004-12-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-6835378-B2 |
| titleOfInvention |
Method and compositions for inhibiting thrombin-induced coagulation |
| abstract |
A method of achieving safe and effective treatment or prevention of potentially harmful blood clots, or in inhibiting the coagulation of blood when so desired such as during a wide array of disease conditions including stroke, myocardial infarction, sickle-cell crisis and venous thrombosis, is provided by the administration of a fibrinogen-binding protein capable of binding at the N-terminal Bbeta chain of fibrinogen, such as SdrG or Fbe, or their respective binding regions such as the A domain. In addition, compositions comprising effective amounts of the fibrinogen-binding proteins are also provided. The present anti-coagulation compositions have been shown to inhibit thrombin-induced fibrin clot formation by interfering with the release of fibrinopeptide B and the resulting anti-coagulation effects can be achieved without potential for causing or exacerbating unwanted side effects such as thrombocytopenia associated with prior art anticoagulants such as heparin. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2006110380-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11041003-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2011171285-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8398672-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9283065-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8409239-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9649211-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10092427-B2 |
| priorityDate |
2001-05-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |